KR20070108418A - 면역 치료법 및 개량 백신 - Google Patents

면역 치료법 및 개량 백신 Download PDF

Info

Publication number
KR20070108418A
KR20070108418A KR1020077024846A KR20077024846A KR20070108418A KR 20070108418 A KR20070108418 A KR 20070108418A KR 1020077024846 A KR1020077024846 A KR 1020077024846A KR 20077024846 A KR20077024846 A KR 20077024846A KR 20070108418 A KR20070108418 A KR 20070108418A
Authority
KR
South Korea
Prior art keywords
plasmid
nucleotide sequence
operably linked
protein
cells
Prior art date
Application number
KR1020077024846A
Other languages
English (en)
Korean (ko)
Inventor
종 제이. 김
빈 왕
진 디. 보이어
데이비드 비. 웨이너
벨판디 아이야부
Original Assignee
더 트러스티스 오브 더 유니버시티 오브 펜실바니아
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 filed Critical 더 트러스티스 오브 더 유니버시티 오브 펜실바니아
Publication of KR20070108418A publication Critical patent/KR20070108418A/ko

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
KR1020077024846A 1996-10-23 1997-10-23 면역 치료법 및 개량 백신 KR20070108418A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2861396P 1996-10-23 1996-10-23
US60/028,613 1996-10-23

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020057008602A Division KR20050053796A (ko) 1996-10-23 1997-10-23 면역 치료법 및 개량 백신

Publications (1)

Publication Number Publication Date
KR20070108418A true KR20070108418A (ko) 2007-11-09

Family

ID=21844431

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020057008602A KR20050053796A (ko) 1996-10-23 1997-10-23 면역 치료법 및 개량 백신
KR1020077024846A KR20070108418A (ko) 1996-10-23 1997-10-23 면역 치료법 및 개량 백신
KR1020047021499A KR100629835B1 (ko) 1996-10-23 1997-10-23 면역 치료법 및 개량 백신
KR1019997003507A KR100780158B1 (ko) 1996-10-23 1997-10-23 면역 치료법 및 개량 백신

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020057008602A KR20050053796A (ko) 1996-10-23 1997-10-23 면역 치료법 및 개량 백신

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020047021499A KR100629835B1 (ko) 1996-10-23 1997-10-23 면역 치료법 및 개량 백신
KR1019997003507A KR100780158B1 (ko) 1996-10-23 1997-10-23 면역 치료법 및 개량 백신

Country Status (8)

Country Link
EP (1) EP0958364A4 (ja)
JP (3) JP2001507216A (ja)
KR (4) KR20050053796A (ja)
CN (2) CN1257976C (ja)
AU (1) AU729579B2 (ja)
BR (1) BR9712852A (ja)
CA (3) CA2751712C (ja)
WO (1) WO1998017799A1 (ja)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002301344B2 (en) * 1998-05-06 2005-01-13 Association Francais Contre Les Myopathies Use of a nuclease inhibitor or interleukin-10 (IL-10) for the preparation of a therapeutic composition for improving transfection of a polynucleotide into a cell and compositions useful in gene therapy
JP2002513775A (ja) 1998-05-06 2002-05-14 トランジェーヌ、ソシエテ、アノニム 細胞の中へのポリヌクレオチドのトランスフェクションを改良する治療組成物を調製するためのヌクレアーゼインヒビターまたはインターロイキン−１０（ｉｌ−１０）の使用、および遺伝子治療に有用な組成物
WO1999056775A1 (en) * 1998-05-07 1999-11-11 Akzo Nobel N.V. Use of interleukin-18 as vaccine adjuvant
US6316420B1 (en) * 1998-07-28 2001-11-13 Technion Research And Development Foundation Ltd. DNA cytokine vaccines and use of same for protective immunity against multiple sclerosis
EP1168918A4 (en) * 1999-03-03 2002-08-21 Univ Pennsylvania VACCINE AND GENE THERAPY COMPOSITIONS AND METHOD FOR THEIR PRODUCTION AND USE
EP1173573A1 (en) * 1999-04-23 2002-01-23 Pharmexa A/S Method for down-regulating il5 activity
GEP20053446B (en) * 1999-05-13 2005-02-25 Wyeth Corp Adjuvant Combination Formulations
US6943152B1 (en) * 1999-06-10 2005-09-13 Merial DNA vaccine-PCV
CA2395840A1 (en) * 1999-12-27 2001-07-05 The University Of Manitoba Genetic vaccines for the production of chicken egg-yolk antibodies against enterotoxigenic escherichia coli and other pathogens
US7754201B2 (en) 2000-06-02 2010-07-13 GenPhar, Inc Method of vaccination through serotype rotation
US6544780B1 (en) 2000-06-02 2003-04-08 Genphar, Inc. Adenovirus vector with multiple expression cassettes
US7092633B2 (en) 2000-11-14 2006-08-15 University Of Texas System Board Of Regents System and method for configuring optical circuits
JP2002221520A (ja) * 2001-01-29 2002-08-09 Sumitomo Chem Co Ltd 免疫型の予測方法
UA82647C2 (uk) * 2001-03-27 2008-05-12 Юниверсити Оф Саскачеван Спосіб культивування цирковірусу ссавця
KR20030012199A (ko) * 2001-07-31 2003-02-12 (주)지노첵 사이토카인 유전자를 유효성분으로 포함하는 ｄｎａ 백신
DE60329461D1 (de) 2002-01-17 2009-11-12 Polymun Scient Immunbio Forsch Antiidiotypische antikörper die hiv-1 neutralisierende antikörper induzieren
GB0223696D0 (en) * 2002-10-14 2002-11-20 Ml Lab Plc Improved immunotherapy
CA2509980C (en) 2002-11-12 2012-12-18 Albert B. Deisseroth Adenoviral vector vaccine
AU2003297155B2 (en) 2002-12-16 2010-03-18 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant vaccine viruses expressing IL-15 and methods of using the same
US20040146486A1 (en) * 2003-01-24 2004-07-29 Juan Sun Hybrid vector system for use as a vaccine
WO2004069272A2 (en) * 2003-02-05 2004-08-19 Movecare Ltd Adjuvant combination for use in the immunization of a mamal comprising il2 and il12
NZ570709A (en) * 2003-06-13 2010-04-30 Univ Pennsylvania Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same
EP1687334B1 (en) 2003-11-24 2014-01-08 MicroVAX, LLC Mucin antigen vaccine
US8828957B2 (en) 2003-12-11 2014-09-09 Microvax, Llc Methods for generating immunity to antigen
JP4696079B2 (ja) 2003-12-17 2011-06-08 ヤンセン アルツハイマー イミュノセラピー Ａβ免疫原性ペプチド担体結合物およびそれの製造方法
SG149013A1 (en) 2003-12-17 2009-01-29 Wyeth Corp Immunogenic peptide carrier conjugates and methods of producing same
GB0410220D0 (en) 2004-05-07 2004-06-09 Kirkham Lea Ann Mutant pneumolysin proteins
TW200613554A (en) 2004-06-17 2006-05-01 Wyeth Corp Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
JP4903159B2 (ja) * 2005-04-20 2012-03-28 ディナベック株式会社 アルツハイマー病の治療のための安全性に優れた鼻腔内投与可能遺伝子ワクチン
EP3255141B1 (en) 2006-07-13 2021-12-01 Wyeth LLC Production of antibodies with improved glycosylation pattern
US8192951B2 (en) 2006-11-03 2012-06-05 Wyeth Llc Glycolysis-inhibiting substances in cell culture
DK2115126T3 (en) 2007-03-02 2015-05-04 Wyeth Llc Use of copper and glutamate in cell culture for the preparation of polypeptides
JP5873717B2 (ja) 2008-04-04 2016-03-01 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Ｉｌ−２８及び組成物を用いたワクチン及び免疫治療薬並びにその使用方法
WO2010051820A1 (en) * 2008-11-10 2010-05-14 Aarhus Universitet Multiplexed cytokine vaccination
CA2760446C (en) 2009-04-30 2018-01-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inducible interleukin-12
US20130197612A1 (en) * 2010-02-26 2013-08-01 Jack W. Lasersohn Electromagnetic Radiation Therapy
CN102370979B (zh) * 2011-10-10 2013-05-01 中国人民解放军第四军医大学 一种针对人TNF-α分子的自体疫苗的构建方法
AU2013292617A1 (en) 2012-07-19 2015-01-22 Zoetis Llc Bovine influenza C virus compositions
AU2013295770A1 (en) 2012-07-27 2015-01-29 Zoetis Services Llc Tick toxin compositions
RU2747857C2 (ru) 2013-03-15 2021-05-17 Ин3Био Лтд. Самособирающиеся синтетические белки
US20160008449A1 (en) 2013-03-15 2016-01-14 Zoetis Services Llc CROSS-PROTECTION OF BOVINES AGAINST B. trehalosi INFECTION BY A MULTI-VALENT VACCINE
KR20230062674A (ko) 2013-03-15 2023-05-09 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 암 백신 및 이를 이용한 치료 방법
PL3334454T3 (pl) 2015-08-14 2023-01-30 Zoetis Services Llc Kompozycje mycoplasma bovis
EP3402878A1 (en) 2016-01-11 2018-11-21 Zoetis Services LLC Novel cross protective vaccine compositions for porcine epidemic diarrhea virus
GB201703529D0 (en) 2017-03-06 2017-04-19 Cambridge Entpr Ltd Vaccine composition
EP4317422A3 (en) 2017-04-13 2024-05-01 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
KR102637862B1 (ko) 2017-12-13 2024-02-19 이노비오 파마수티컬즈, 인크. 메소텔린을 표적으로 하는 암 백신 및 이의 용도
EP3866813A4 (en) 2018-10-17 2022-08-03 Senti Biosciences, Inc. COMBINATORY CANCER IMMUNOTHERAPY
US11419898B2 (en) 2018-10-17 2022-08-23 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
EP3897691A4 (en) * 2018-12-21 2022-08-31 The Regents of the University of California IL-10 VACCINES AND THEIR USES
CN110170049B (zh) * 2019-06-01 2023-07-04 山西农业大学 一种用于鸡球虫病活疫苗的细胞因子基因佐剂
WO2023177655A1 (en) 2022-03-14 2023-09-21 Generation Bio Co. Heterologous prime boost vaccine compositions and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1984001575A1 (en) * 1982-10-11 1984-04-26 Nat Biolog Standards Board Polypeptides useful in vaccination against enteroviruses
ZA875681B (en) * 1986-08-01 1988-04-27 Commw Scient Ind Res Org Recombinant vaccine
US5457038A (en) * 1988-11-10 1995-10-10 Genetics Institute, Inc. Natural killer stimulatory factor
US5238823A (en) * 1990-08-22 1993-08-24 Veterinary Infectious Disease Organization Interleukin-2-leukotoxin gene fusions and uses thereof
IL112820A0 (en) * 1994-03-07 1995-05-26 Merck & Co Inc Coordinate in vivo gene expression
CA2201592A1 (en) * 1994-10-03 1996-04-18 The Government Of The United States Of America, Represented By The Secre Tary, Department Of Health And Human Services Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule b7 gene in a recombinant virus expressing system

Also Published As

Publication number Publication date
JP2001507216A (ja) 2001-06-05
AU729579B2 (en) 2001-02-01
BR9712852A (pt) 1999-11-16
CA2745736C (en) 2016-11-22
JP2008194046A (ja) 2008-08-28
CN1257976C (zh) 2006-05-31
AU5002297A (en) 1998-05-15
KR100629835B1 (ko) 2006-09-29
CA2751712C (en) 2016-11-22
KR100780158B1 (ko) 2007-11-27
CN1868545A (zh) 2006-11-29
CN1242045A (zh) 2000-01-19
KR20050008860A (ko) 2005-01-21
KR20050053796A (ko) 2005-06-08
EP0958364A1 (en) 1999-11-24
JP2009232860A (ja) 2009-10-15
CA2751712A1 (en) 1998-04-30
WO1998017799A1 (en) 1998-04-30
KR20000052710A (ko) 2000-08-25
CA2269074A1 (en) 1998-04-30
CA2745736A1 (en) 1998-04-30
EP0958364A4 (en) 2001-10-31

Similar Documents

Publication Publication Date Title
KR100780158B1 (ko) 면역 치료법 및 개량 백신
WO1998017799A9 (en) Immunotherapy and improved vaccines
EP1078093B1 (en) Vaccines, immunotherapeutics and methods for using the same
US8202847B2 (en) Mutant human CD80 and compositions for and methods of making and using the same
KR100620481B1 (ko) 개선된 백신
AU774265B2 (en) Vaccines and gene therapy compositions and methods of making and using the same
US20040223974A1 (en) Vaccines, immunotherapeutics and methods for using the same
AU2001261590B2 (en) Vaccines, immunotherapeutics and methods for using the same
Kim Rational vaccine design through the use of molecular adjuvants
AU2007200484A1 (en) Vaccines, immunotherapeutics and methods for using the same
AU2001261590A1 (en) Vaccines, immunotherapeutics and methods for using the same

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application